ArticleTissue engineering. Part A2011
Release of bioactive adeno-associated virus from fibrin scaffolds: effects of fibrin glue concentrations.
Article in Tissue engineering. Part A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Biomaterial-mediated blood clot formation: a key to unlocking osteogenic synergy for bone regeneration.Bone research · 2026Review
- Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants.Science advances · 2025Article
- Combined sustained and triggered release for sequential viral-transduction from collagen-based scaffolds for tissue regeneration.Biomaterials science · 2025Article
- Engineering gene-activated bioprinted scaffolds for enhancing articular cartilage repair.Materials today. Bio · 2024Review
- A review of advanced hydrogels for cartilage tissue engineering.Frontiers in bioengineering and biotechnology · 2024Review
- In situ-formable, dynamic crosslinked poly(ethylene glycol) carrier for localized adeno-associated virus infection and reduced off-target effects.Communications biology · 2023Article
- Gene Therapy for Regenerative Medicine.Pharmaceutics · 2023Review
- Women's contribution to stem cell research for osteoarthritis: an opinion paper.Frontiers in cell and developmental biology · 2023Review
- Advances in Biomaterial-Mediated Gene Therapy for Articular Cartilage Repair.Bioengineering (Basel, Switzerland) · 2022Review
- Optimization of Fibrin Scaffolds to Study Friction in Cultured Mesothelial Cells.International journal of molecular sciences · 2022Article
- Enhancing Stem Cell Therapy for Cartilage Repair in Osteoarthritis-A Hydrogel Focused Approach.Gels (Basel, Switzerland) · 2021Review
- Targeted nanoscale therapeutics for myocardial infarction.Biomaterials science · 2021Review
- Recent advances in polymeric biomaterials-based gene delivery for cartilage repair.Bioactive materials · 2020Article
- Biomaterial Based Strategies for Engineering New Lymphatic Vasculature.Advanced healthcare materials · 2020Review
- rAAV-Mediated Overexpression of SOX9 and TGF-β via Carbon Dot-Guided Vector Delivery Enhances the Biological Activities in Human Bone Marrow-Derived Mesenchymal Stromal Cells.Nanomaterials (Basel, Switzerland) · 2020Article
- Enhanced Chondrogenic Differentiation Activities in Human Bone Marrow Aspirates viaPharmaceutics · 2020Article
- AAVR-Displaying Interfaces: Serotype-Independent Adeno-Associated Virus Capture and Local Delivery Systems.Molecular therapy. Nucleic acids · 2019Article
- Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair.Nature reviews. Rheumatology · 2019Review
- Effects of combined rAAV-mediated TGF-β and sox9 gene transfer and overexpression on the metabolic and chondrogenic activities in human bone marrow aspirates.Journal of experimental orthopaedics · 2017Article
- Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.Tissue engineering. Part B, Reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Fibrin glue (FG) is used in a variety of clinical applications and in the laboratory for localized and sustained release of factors potentially important for tissue engineering. However, the effect of different fibrinogen concentrations on FG scaffold delivery of bioactive adeno-associated viruses (AAVs) has not been established. This study was performed to test the hypothesis that FG concentration alters AAV release profiles, which affect AAV bioavailability. Gene transfer efficiency of AAV-GFP released from FG was measured using HEK-293 cells. Bioactivity of AAV transforming growth factor-beta1 (TGF-β(1)) released from FG was assessed using the mink lung cell assay, and by measuring induction of cartilage-specific gene expression in human mesenchymal stem cells (hMSCs). Nondiluted FG had longer clotting times, smaller pore sizes, thicker fibers, and slower dissolution rate, resulting in reduced release of AAV. AAV release and gene transfer efficiency was higher with 25% and 50% FG than with the 75% and 100% FG. AAV-TGF-β(1) released from dilute-FG transduced hMSCs, resulting in higher concentrations of bioactive TGF-β(1) and greater upregulation of cartilage-specific gene expression compared with hMSC from undiluted FG. This study, showing improved release, transduction efficiency, and chondrogenic effect on hMSC of bioactive AAV-TGF-β(1) released from diluted FG, provides information important to optimization of this clinically available scaffold for therapeutic gene delivery, both in cartilage regeneration and for other tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.